Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Ann L. Oberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2539-9807; OpenAlex author ID A5069976109; NIH RePORTER profile ID 8853253. Sources: ClinicalTrials.gov.

Their work

Papers
51 (first author 2, last author 3)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
1
Collaborators
112
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 3 papers · 2014: 3 papers · 2015: 3 papers · 2016: 3 papers · 2017: 5 papers · 2018: 3 papers · 2019: 3 papers · 2020: 5 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers, 1 trial · 2025: 2 papers · 2026: 8 papers, 2 grants

Papers 50 of 51

  1. Artificial Intelligence-Estimated Intrapancreatic Fat and Its Relationship to Familial and Germline Pancreatic Cancer Risk. Co-author DOI 10.1002/ueg2.70279↗
  2. Socioeconomic deprivation, rurality, and travel distance negatively impact survival in early-stage pancreatic ductal adenocarcinoma but are not associated with… Co-author DOI 10.1016/j.canep.2026.103124↗
  3. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  4. Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor … Co-author DOI 10.1158/1078-0432.ccr-25-3297↗
  5. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  6. Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0343022↗
  7. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  8. Mutational signature landscape of pancreatic cancer genomes from nine countries Co-author DOI 10.64898/2026.10.21.26365999↗
  9. Reply to the Letter to the Editor regarding “Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early … Last author DOI 10.1016/j.pan.2025.04.017↗
  10. Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. Co-author DOI 10.1530/erc-24-0142↗
  11. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Last author DOI 10.1016/j.pan.2024.10.012↗
  12. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  13. Machine Learning Models for Pancreatic Cancer Risk Prediction Using Electronic Health Record Data-A Systematic Review and Assessment. Co-author DOI 10.14309/ajg.0000000000002870↗
  14. Polycyclic Aromatic Hydrocarbons and Pancreatic Cancer: An Analysis of the Blood Biomarker, r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and Selec… Co-author DOI 10.3390/nu16050688↗
  15. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  16. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. Co-author DOI 10.1158/1055-9965.epi-21-0745↗
  17. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  18. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  19. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-20-1279↗
  20. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. Co-author DOI 10.1158/1940-6207.capr-20-0403↗
  21. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  22. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  23. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Co-author DOI 10.1158/1055-9965.epi-19-1597↗
  24. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  25. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  26. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Co-author DOI 10.1093/jnci/djx272↗
  27. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  28. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Co-author DOI 10.1158/1055-9965.epi-18-1235↗
  29. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. First author DOI 10.1038/gim.2017.85↗
  30. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  31. Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Co-author DOI 10.1093/carcin/bgy072↗
  32. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1016/j.gie.2016.11.014↗
  33. Immunosuppressive CD14+HLA-DR lo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. Co-author DOI 10.1080/2162402x.2016.1252013↗
  34. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Co-author DOI 10.1126/scitranslmed.aah5583↗
  35. Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-17-0100↗
  36. Association between Alcohol Consumption, Folate Intake, and Risk of Pancreatic Cancer: A Case-Control Study. Co-author DOI 10.3390/nu9050448↗
  37. Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. First author DOI 10.1093/carcin/bgw022↗
  38. Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. Last author DOI 10.1200/jco.2015.63.3511↗
  39. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  40. Detection of DNA damage in peripheral blood mononuclear cells from pancreatic cancer patients. Co-author DOI 10.1002/mc.22189↗
  41. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Co-author DOI 10.1007/s10552-015-0652-y↗
  42. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  43. Fatty acids found in dairy, protein and unsaturated fatty acids are associated with risk of pancreatic cancer in a case-control study. Co-author DOI 10.1002/ijc.28525↗
  44. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  45. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-13-0557-t↗
  46. Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer. Co-author DOI 10.1007/s12029-012-9441-y↗
  47. Polymorphisms in metabolism/antioxidant genes may mediate the effect of dietary intake on pancreatic cancer risk. Co-author DOI 10.1097/mpa.0b013e3182968e00↗
  48. Meat-related mutagens and pancreatic cancer: null results from a clinic-based case-control study. Co-author DOI 10.1158/1055-9965.epi-13-0343↗
  49. Fruit and vegetable consumption is inversely associated with having pancreatic cancer. Co-author DOI 10.1007/s10552-011-9838-0↗
  50. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Co-author DOI 10.1158/1940-6207.capr-11-0146↗

Trials 1

  1. Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts Principal investigator NCT06271291↗

Grants 2

  1. Multifactor risk scores with susceptibility gene mutations to enhance risk assessment of pancreatic cancer R01CA272668↗
  2. Management and Data Coordination Unit for PCDC U24CA274496↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gloria M. Petersen · 25 shared papers, 2011–2024 · strength 1.79
  2. Shounak Majumder · 7 shared papers, 2024–2026 · strength 1.73
  3. Kari G. Rabe · 19 shared papers, 2011–2026 · strength 1.62
  4. Samuel O. Antwi · 10 shared papers, 2015–2026 · strength 1.19
  5. Kenneth S. Zaret · 5 shared papers, 2017–2026 · strength 0.86
  6. Michael Goggins · 4 shared papers, 2019–2026 · strength 0.72
  7. Lynette M. Smith · 3 shared papers, 2024–2026 · strength 0.66
  8. Bradford Chong · 2 shared papers, 2024–2026 · strength 0.61
  9. Anup Kumar Mishra · 2 shared papers, 2024–2026 · strength 0.51
  10. Brianna M. Krusen · 2 shared papers, 2026 · strength 0.51
  11. Rick J. Jansen · 8 shared papers, 2011–2024 · strength 0.51
  12. Hugues Sicotte · 3 shared papers, 2020–2026 · strength 0.50
  13. Ryan Michael Carr · 2 shared papers, 2025–2026 · strength 0.49
  14. Douglas W. Mahoney · 2 shared papers, 2024–2025 · strength 0.43
  15. Qiao-Li Wang · 2 shared papers, 2024–2025 · strength 0.43
  16. Randall E. Brand · 2 shared papers, 2024–2025 · strength 0.43
  17. Gregory A. Coté · 2 shared papers, 2024–2025 · strength 0.43
  18. Erica L. Carpenter · 2 shared papers, 2021–2026 · strength 0.41
  19. Suyu Liu · 2 shared papers, 2024–2026 · strength 0.39
  20. Brian Matthew Wolpin · 2 shared papers, 2024–2026 · strength 0.39
  21. Sudhir Srivastava · 2 shared papers, 2024–2026 · strength 0.39
  22. Shruti Chandra · 2 shared papers, 2022–2025 · strength 0.36
  23. Amit Mahipal · 2 shared papers, 2021–2025 · strength 0.35
  24. Laufey Thora Amundadottir · 2 shared papers, 2018–2026 · strength 0.32
  25. Aminah Jatoi · 3 shared papers, 2017–2021 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.